Table 2 Univariate and multivariate analysis for OS
From: A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
Covariate | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age ≥ 69 years | 0.6389 (0.3691–1.1060) | 0.057 | – | – |
Sex | 1.4 (0.7892–2.485) | 0.247 | – | – |
Weight ≥ 69.5 kg | 1.1999 (0.6606–2.1794) | 0.543 | – | – |
Height > 168 cm | 0.9492 (0.4884–1.8445) | 0.876 | – | – |
Liver metastasis | 3.6912 (2.0123–6.7710) | 0.000 | 3.0637 (1.6693–.623) | 0.0003 |
Lung metastasis | 0.4954 (0.2858–0.8587) | 0.017 | 0.6209 (0.3564–1.082 | 0.0925 |
Lymph node metastasis | 0.4954 (0.2858–0.8587) | 0.2723 | – | – |
Only lymph node metastasis | 0.4482 (0.2363–0.8502) | 0.0145 | – | – |
Brain metastasis | 0.9460 (0.4728–1.8927) | 0.876 | – | – |
Malignant pleural effusion | 0.991 | – | – | |
Bone metastasis | 1.4029 (0.8022–2.4535) | 0.2375 | – | – |
Adrenal gland metastasis | 1.1271 (0.5095–2.4933) | 0.7689 | – | – |
N. of metastatic sites | 1.1610 (0.7966–1.6921) | 0.4395 | – | – |
ECOG PS | 2.706 (1.774–4.126) | < 0.0001 | 2.588 (1.655–4.046) | < 0.0001 |
Line of treatment | 1.1507 (0.7571–1.7488) | 0.5133 | – | – |
Global | < 0.0001 | |||